Increased activity of the diastrophic dysplasia sulfate transporter in otosclerosis and its inhibition by sodium fluoride

被引:19
作者
Grayeli, TB
Escoubet, B
Bichara, M
Julien, N
Silve, C
Friedlander, G
Sterkers, T
Ferrary, E
机构
[1] Univ Paris 07, Fac Xavier Bichat, INSERM, EMI U 0112, F-75870 Paris 18, France
[2] Hop Beaujon, AP HP, Dept Otolaryngol Head & Neck Surg, Clichy, France
[3] Univ Paris 07, Fac Xavier Bichat, INSERM, Unite 426, F-75870 Paris, France
关键词
otosclerosis; hearing loss; diastrophic dysplasia sulfate transporter; pathophysiology; sodium fluoride;
D O I
10.1097/00129492-200311000-00005
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Hypothesis: This study investigates the function of the diastrophic dysplasia sulfate transporter (DTDST) in otosclerotic bone and the effect on it of sodium fluoride (NaF). Background: Otosclerosis is a localized bone dystrophy with increased bone turnover. DTDST is implicated in the regulation of the bone turnover. Materials and Methods: Primary cultures of cells were obtained from the stapes and external auditory canal (EAC) of 26 patients with otosclerosis and from nine control patients. Sulfate uptake was quantified under basal conditions and with NaF. The NaF signaling pathways were investigated using forskolin and verapamil. Results: The relative initial rates of sulfate uptake and the apparent Vmax values were: otosclerotic stapes > EAC > control stapes = control EAC. The sulfate uptake by the otosclerotic stapes was correlated with the loss of sensorineural hearing. The amounts of DTDST mRNA (RNase protection assay) in the four subgroups did not differ. NaF (10(-6)M, I hr) inhibited sulfate uptake by the otosclerotic stapes and EAC cells but not by control samples. Conclusion: The authors believe that whether the increased DTDST activity is a cause or an effect of otosclerosis, it appears to be a specific target for NaF treatment.
引用
收藏
页码:854 / 862
页数:9
相关论文
共 38 条
[1]  
Bodo M, 1995, CELL MOL BIOL, V41, P1039
[2]   Glycosaminoglycan metabolism and cytokine release in normal and otosclerotic human bone cells interleukin-1 treated [J].
Bodo, M ;
Carinci, P ;
Venti, G ;
Giammarioli, M ;
Donti, E ;
Stabellini, G ;
Paludetti, G ;
Becchetti, E .
CONNECTIVE TISSUE RESEARCH, 1997, 36 (03) :231-240
[3]  
BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3
[4]  
BRETLAU P, 1989, AM J OTOL, V10, P20
[5]   OTOSPONGIOSIS AND SODIUM-FLUORIDE - A BLIND EXPERIMENTAL AND CLINICAL-EVALUATION OF THE EFFECT OF SODIUM-FLUORIDE TREATMENT IN PATIENTS WITH OTOSPONGIOSIS [J].
BRETLAU, P ;
HANSEN, HJ ;
CAUSSE, J ;
JOHNSEN, NJ ;
CAUSSE, JB ;
SALOMON, G .
ANNALS OF OTOLOGY RHINOLOGY AND LARYNGOLOGY, 1985, 94 (02) :103-107
[6]   Fluoride: Mode of action [J].
Caverzasio, J ;
Palmer, G ;
Bonjour, JP .
BONE, 1998, 22 (06) :585-589
[7]   BIOCHEMICAL AND CYTOLOGICAL EXPLANATION OF COCHLEAR OTOSCLEROSIS [J].
CHEVANCE, LG .
ACTA OTO-LARYNGOLOGICA, 1976, 81 (3-4) :200-203
[8]   PATHOLOGY OF OTOSCLEROSIS - A REVIEW [J].
DAVIS, GL .
AMERICAN JOURNAL OF OTOLARYNGOLOGY, 1987, 8 (05) :273-281
[9]  
DONALDSON JA, 1993, OTOLARYNGOLOGY HEAD, V4, P2997
[10]   SULFATE TRANSPORT IN HUMAN-LUNG FIBROBLASTS (IMR-90) [J].
ELGAVISH, A ;
SMITH, JB ;
PILLION, DJ ;
MEEZAN, E .
JOURNAL OF CELLULAR PHYSIOLOGY, 1985, 125 (02) :243-250